Robinson-White Audrey J, Hsiao Hui-Pin, Leitner Wolfgang W, Greene Elizabeth, Bauer Andrew, Krett Nancy L, Nesterova Maria, Stratakis Constantine A
Section on Endocrinology and Genetics, Program on Developmental Endocrinology and Genetics, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Clin Endocrinol Metab. 2008 Mar;93(3):1020-9. doi: 10.1210/jc.2007-2331. Epub 2007 Dec 11.
Protein kinase A (PKA) affects cell proliferation in many cell types and is a potential target for cancer treatment. PKA activity is stimulated by cAMP and cAMP analogs. One such substance, 8-Cl-cAMP, and its metabolite 8-Cl-adenosine (8-Cl-ADO) are known inhibitors of cancer cell proliferation; however, their mechanism of action is controversial. We have investigated the antiproliferative effects of 8-Cl-cAMP and 8-CL-ADO on human thyroid cancer cells and determined PKA's involvement.
We employed proliferation and apoptosis assays and PKA activity and cell cycle analysis to understand the effect of 8-Cl-ADO and 8-Cl-cAMP on human thyroid cancer and HeLa cell lines.
8-Cl-ADO inhibited proliferation of all cells, an effect that lasted for at least 4 d. Proliferation was also inhibited by 8-Cl-cAMP, but this inhibition was reduced by 3-isobutyl-1-methylxanthine; both drugs stimulated apoptosis, and 3-isobutyl-1-methylxanthine drastically reduced 8-Cl-cAMP-induced cell death. 8-Cl-ADO induced cell accumulation in G1/S or G2/M cell cycle phases and differentially altered PKA activity and subunit levels. PKA stimulation or inhibition and adenosine receptor agonists or antagonists did not significantly affect proliferation.
8-Cl-ADO and 8-Cl-cAMP inhibit proliferation, induce cell cycle phase accumulation, and stimulate apoptosis in thyroid cancer cells. The effect of 8-Cl-cAMP is likely due to its metabolite 8-Cl-ADO, and PKA does not appear to have direct involvement in the inhibition of proliferation by 8-Cl-ADO. 8-Cl-ADO may be a useful therapeutic agent to be explored in aggressive thyroid cancer.
蛋白激酶A(PKA)在多种细胞类型中影响细胞增殖,是癌症治疗的一个潜在靶点。PKA活性受环磷酸腺苷(cAMP)及其类似物刺激。一种这样的物质,8-氯-cAMP及其代谢产物8-氯腺苷(8-Cl-ADO)是已知的癌细胞增殖抑制剂;然而,它们的作用机制存在争议。我们研究了8-氯-cAMP和8-Cl-ADO对人甲状腺癌细胞的抗增殖作用,并确定了PKA的参与情况。
我们采用增殖和凋亡分析以及PKA活性和细胞周期分析,以了解8-Cl-ADO和8-氯-cAMP对人甲状腺癌和HeLa细胞系的影响。
8-Cl-ADO抑制所有细胞的增殖,这种作用持续至少4天。8-氯-cAMP也抑制增殖,但这种抑制作用被3-异丁基-1-甲基黄嘌呤减弱;两种药物均刺激细胞凋亡,且3-异丁基-1-甲基黄嘌呤显著降低8-氯-cAMP诱导的细胞死亡。8-Cl-ADO诱导细胞在G1/S或G2/M细胞周期阶段积累,并不同程度地改变PKA活性和亚基水平。PKA的刺激或抑制以及腺苷受体激动剂或拮抗剂对增殖没有显著影响。
8-Cl-ADO和8-氯-cAMP抑制甲状腺癌细胞的增殖,诱导细胞周期阶段积累,并刺激细胞凋亡。8-氯-cAMP的作用可能归因于其代谢产物8-Cl-ADO,并且PKA似乎没有直接参与8-Cl-ADO对增殖的抑制作用。8-Cl-ADO可能是一种可用于侵袭性甲状腺癌治疗的有用药物。